# Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Source: https://onco.cc/trials/nct07521605/  
OnCo record `nct07521605` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of irinotecan (and liposomal irinotecan), capecitabine and camrelizumab in colorectal cancer, run by Guangdong Provincial People's Hospital, not yet recruiting.

## Summary

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer is a phase 2, interventional study registered as NCT07521605 by Guangdong Provincial People's Hospital, with a registry enrolment figure of 44 participants, started 2026-05-20 and due to reach its primary completion in 2031-12-31. Interventions recorded: Short-Course Radiotherapy; Liposomal Irinotecan (nal-IRI); Capecitabine; Camrelizumab. Conditions listed: Rectal Cancer Patients. Primary outcome: Complete Response Rate. Colorectal eligibility wording from the registry: "Histologically confirmed diagnosis of rectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07521605
- Phase: 2
- Setting: Short-Course Radiotherapy Followed by Liposomal Irinotecan, Capecitabine, and Camrelizumab as Neoadjuvant Therapy for Locally Advanced pMMR/MSS Low Rectal Cancer: A Prospective Single-Arm Phase II Trial Protocol
- Sponsor: Guangdong Provincial People's Hospital
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT07521605: https://clinicaltrials.gov/study/NCT07521605

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07521605.json